Discussion
cancer, encephalitis, tumour, HSV meningitis
SOLID TUMOUR, TUMOURS, CANCER, ENCEPHALITIS, TUMOUR
In this first-in-human clinical trial of CAN-3110, HSV meningitis or encephalitis was not seen, despite ongoing CAN-3110 persistence/replication for several months and maintenance of the A major challenge faced by solid tumour immunotherapy is to create a microenvironment that is favourable for an efficient immune response against cancer cellsThe finding that positive HSV1 serology before or after CAN-3110 treatment was a highly significant independent predictor of response was unexpected based on previously reported trials of other oHSVsThe observation that CAN-3110 was immunohistochemically detected in almost half of the injected tumours several months (and even years in some patients) and even in one uninjected tumour suggests ongoing replication of the agent. Other oncolytic viruses, such as ICP34.5-defective oHSV, have rarely been found in injected human tumours, particularly after several weeks